Compare Merck & Co., Inc. (MRK) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs AT&T Inc. — how do they compare? Merck & Co., Inc. trades at $146.2 (market cap $351.28B), while AT&T Inc. trades at $22.24 (market cap $170.42B). The key difference: Merck & Co., Inc. is far larger — about 2.1× AT&T Inc.'s market cap, and AT&T Inc. pays the higher dividend (4.46%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and AT&T Inc. for 118 Days on average.
| MRK | T | |
|---|---|---|
Market Cap | $351.28B | $170.42B |
Volume | 7,969,665 | 50,780,036 |
Sector | Health | Media |
52-Week High | $156.43 | $29.10 |
52-Week Low | $82.49 | $20.49 |
Typical Hold Time | 98 Days | 118 Days |
Enterprise Value | $398.04B | $315.74B |
Dividend Yield | 2.39% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
AT&T (T) trades at $22.18, down 9.38% in the past 24 hours, reflecting recent market pressure despite strong fundamentals. The company shows robust profitability with a 16.94% net income margin and attractive valuation metrics including a P/E of 8.21. Recent earnings beats and a $3 billion fiber deal with Corning highlight operational strength, while technical indicators show mixed signals with overall bullish sentiment.
The stock offers value with a consensus price target of $27.50, representing 24% upside potential. Key opportunities include fiber expansion and wireless growth, balanced against risks from heavy debt load and competitive pressures. The 4% dividend yield provides income support, though investors should monitor debt management and revenue trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
